Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Hemogenyx Pharmaceuticals logo
GBX 182.48 -2.77 (-1.50%)
As of 09:59 AM Eastern

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Key Stats

Today's Range
180
187
50-Day Range
167.25
344
52-Week Range
160
1,200
Volume
61,461 shs
Average Volume
29,742 shs
Market Capitalization
£6.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HEMO Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Hemogenyx Pharmaceuticals Announces Key Corporate Changes
See More Headlines

HEMO Stock Analysis - Frequently Asked Questions

Hemogenyx Pharmaceuticals' stock was trading at GBX 402 at the beginning of 2025. Since then, HEMO stock has decreased by 54.6% and is now trading at GBX 182.48.
View the best growth stocks for 2025 here
.

Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter.

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
9/30/2020
Today
4/24/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:HEMO
Previous Symbol
LON:SILF
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-6,890.55
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 89.23 per share
Price / Cash Flow
2.05
Book Value
GBX 0.25 per share
Price / Book
740.71

Miscellaneous

Free Float
N/A
Market Cap
£6.50 million
Optionable
Not Optionable
Beta
3.14
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (LON:HEMO) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners